Kelyniam Global Secures Exclusive U.S. License for Evonik's VESTAKEEP® Fusion Biomaterial in Cranial Implants
Kelyniam Global (OTC: KLYG) secured an exclusive U.S. license from Evonik to market VESTAKEEP® Fusion, a bi-calcium phosphate–infused PEEK material, for cranial, craniofacial, and maxillofacial implants.
The agreement provides two years of exclusivity with an option to renew and names Modern Plastics as the distributor to ensure supply. Kelyniam said the material's osteoconductive properties support bone growth and integration and that the license expands its regenerative product lineup alongside existing options from Finceramica and Osteopore.
Kelyniam Global (OTC: KLYG) ha ottenuto un licenza esclusiva negli Stati Uniti da Evonik per commercializzare VESTAKEEP® Fusion, un materiale PEEK arricchito con bio-calciofosfato, per impianti cranici, crano-facciali e maxillo-facciali.
L'accordo prevede due anni di esclusività con opzione di rinnovo e nomina Modern Plastics come distributore per garantire l'approvvigionamento. Kelyniam ha dichiarato che le proprietà osteoconducenti del materiale supportano la crescita e l'integrazione ossea e che la licenza amplia la sua linea di prodotti rigenerativi accanto alle opzioni esistenti di Finceramica e Osteopore.
Kelyniam Global (OTC: KLYG) obtuvo una licencia exclusiva en EE. UU. de Evonik para comercializar VESTAKEEP® Fusion, un material PEEK enriquecido con fosfato de calcio bicálcico, para implantes craneales, craneofaciales y maxilofaciales.
El acuerdo ofrece dos años de exclusividad con opción a renovar y nombra a Modern Plastics como distribuidor para garantizar el suministro. Kelyniam afirmó que las propiedades osteoconductivas del material apoyan el crecimiento e la integración ósea y que la licencia amplía su línea de productos regenerativos junto a las opciones existentes de Finceramica y Osteopore.
Kelyniam Global (OTC: KLYG)은 Evonik으로부터 미국 내 독점 라이선스를 확보하여 VESTAKEEP® Fusion을 판매합니다. 이 생체 소재는 생체 칼슘 인산염이 첨가된 PEEK 재료로, 두개골, 두개악 및 악안구 임플란트에 사용됩니다.
계약은 2년간의 독점권을 제공하며 갱신 옵션이 있으며 공급 보장을 위해 Modern Plastics를 배포자로 지정합니다. Kelyniam은 이 재료의 골생성 촉진(osteoconductive) 특성이 골의 성장과 통합을 지원하고 라이선스가 Finceramica와 Osteopore의 기존 옵션과 함께 재생 제품 라인업을 확장한다고 말했습니다.
Kelyniam Global (OTC: KLYG) a obtenu une licence exclusive aux États-Unis d'Evonik pour commercialiser VESTAKEEP® Fusion, un matériau PEEK enrichi en phosphate de calcium bi-calcique, destiné aux implants crâniens, craniofaciaux et maxillo-faciaux.
L'accord prévoit deux ans d'exclusivité avec une option de renouvellement et désigne Modern Plastics comme distributeur pour garantir l'approvisionnement. Kelyniam a déclaré que les propriétés osteoconductives du matériau soutiennent la croissance et l'intégration osseuse et que la licence élargit sa gamme de produits régénératifs aux côtés des options existantes de Finceramica et Osteopore.
Kelyniam Global (OTC: KLYG) sicherte sich eine exklusive Lizenz in den USA von Evonik, um VESTAKEEP® Fusion zu vermarkten, ein PEEK-Material, das mit Kalziumphosphat bi-kalcium-infundiert ist, für Schädel-, Schädel-Kranio- und Kieferimplantate.
Die Vereinbarung gewährt zwei Jahre Exklusivität mit der Option auf Verlängerung und benennt Modern Plastics als Distributor, um die Versorgung sicherzustellen. Kelyniam sagte, die osteokonduktiven Eigenschaften des Materials unterstützten das Knochenwachstum und die Integration, und dass die Lizenz seine regenerative Produktpalette neben den bestehenden Optionen von Finceramica und Osteopore erweitert.
Kelyniam Global (OTC: KLYG) حصلت على ترخيص حصري في الولايات المتحدة من Evonik لتسويق VESTAKEEP® Fusion، وهي مادة PEEK محشوة بفوسفات الكالسيوم الثنائي، لاستخدامها في الزرعات القحفية والقحفية الوجهية والفكية.
توفر الاتفاقية سنتين من الحصرية مع خيار التجديد وتعيين Modern Plastics كموزع لضمان الإمداد. وقالت Kelyniam إن خصائص المادة المحفِّزة للعظم تدعم نمو العظم وتكامله، وأن الترخيص يوسّع مجموعة منتجاتها التجديدية إلى جانب الخيارات الحالية من Finceramica و Osteopore.
- 2-year exclusive U.S. license to market VESTAKEEP Fusion
- Adds a bioceramic-infused PEEK to regenerative cranial portfolio
- Distribution secured through Modern Plastics for supply continuity
- Exclusivity is time-limited to two years, requiring renewal to extend protection
- No financial terms disclosed for the license or expected revenue
- Faces competition from established regenerative options like Finceramica and Osteopore
CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial, craniofacial, and maxillofacial implants. This agreement grants Kelyniam two years of exclusivity with the option for renewal upon mutual agreement.
The license enhances Kelyniam's regenerative product lineup by incorporating VESTAKEEP® Fusion's osteoconductive properties, that promote human bone growth and integration. Distributed through Modern Plastics, a trusted long-term supplier of PEEK materials, this partnership leverages a proven relationship to ensure reliable access and supports Kelyniam's growth in advanced neurosurgical solutions.
This strategic move adds significant value for shareholders by expanding Kelyniam's regenerative medicine portfolio alongside established regenerative options like Finceramica's CustomizedBone (hydroxyapatite) and Osteopore's polycaprolactone products, positioning the company to meet increasing demand for innovative, patient-focused cranial reconstruction.
“We’re proud to introduce VESTAKEEP® Fusion as the latest addition to Kelyniam’s portfolio of innovative cranial and craniofacial solutions,” said Desiree Webb, Chief Operating and Revenue Officer at Kelyniam Global. “Pre-clinical studies have shown that PEEK-containing BCP demonstrates superior osteointegration, and the Fusion BCP implant showcases our ongoing commitment to delivering regenerative technologies that improve patient outcomes and advance the standard of care.”
About Kelyniam Global, Inc.
Kelyniam Global, Inc. (OTC: KLYG) a United States based company, designs, manufactures, and distributes custom cranial and craniofacial implants using advanced biocompatible materials. Renowned for its industry-leading 24-48 hour delivery, Kelyniam partners with surgeons and hospitals to optimize clinical outcomes and reduce costs in neurosurgery. For more information, visit www.kelyniam.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including projections for 2026 revenue growth, distributor expansion impacts, and the effects of recent partnerships and clearances, involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include market competition, regulatory delays, distributor performance variability, economic pressures on healthcare spending, and supply chain disruptions, as detailed in Kelyniam's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kelyniam undertakes no obligation to update these statements except as required by law.
SOURCE Kelyniam Global, Inc. Investor Contact: (860) 590-3034 | info@kelyniam.com
FAQ
What did Kelyniam announce on November 13, 2025 regarding VESTAKEEP Fusion (KLYG)?
How long is Kelyniam's exclusivity for VESTAKEEP Fusion (KLYG)?
Will Kelyniam have reliable access to VESTAKEEP Fusion material (KLYG)?
What clinical benefit does VESTAKEEP Fusion offer for cranial implants (KLYG)?
Does the announcement include financial terms or revenue guidance for Kelyniam (KLYG)?
How does VESTAKEEP Fusion position Kelyniam among competitors like Finceramica and Osteopore (KLYG)?
